SL
BMRN icon

Salomon & Ludwin’s BioMarin Pharmaceuticals BMRN Stock Holding History

Salomon & Ludwin’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.7K Sell
203
-1
-0.5% -$55 ﹤0.01% 1517
2026
Q1 		$11.3K Buy
+204
New +$11.9K ﹤0.01% 1468
2025
Q4 		– Sell
-215
Closed -$11.9K – 2145
2025
Q3 		$11.9K Buy
+215
New +$12.3K ﹤0.01% 1176

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Salomon & Ludwin's BMRN Position: Q2 2026 in Review

Salomon & Ludwin reduced its BioMarin Pharmaceuticals (BMRN) stake by 0.49% in Q2 2026, selling an estimated $55 and leaving 203 shares worth $11.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1517.

Salomon & Ludwin first reported a position in BMRN in Q3 2025 and has held it in 3 quarters since. The position peaked at $11.9K in Q3 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Salomon & Ludwin held 203 shares of BioMarin Pharmaceuticals worth $11.7K as of Q2 2026.
  • Salomon & Ludwin sold 1 BioMarin Pharmaceuticals share in Q2 2026, an estimated $55.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #1517 holding.
  • Salomon & Ludwin first reported a position in BioMarin Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Salomon & Ludwin's BioMarin Pharmaceuticals position peaked at $11.9K in Q3 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.